Expert Review of Clinical Pharmacology最新文献_第2页

Gene therapy in cardiology: pioneering a new era in medical ethics and patient care. 心脏病学中的基因治疗：开创医学伦理和病人护理的新时代。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-01-01 DOI: 10.1080/17512433.2024.2448523

Maria Sara Mauro, Davide Capodanno

引用次数: 0

Methenamine Hippurate in UTI management: a reemerging pharmacological strategy. 尿路感染管理中的盐酸甲基苯丙胺：一种重新出现的药理学策略。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-23 DOI: 10.1080/17512433.2024.2445621

Mehwash Nadeem, Hashim Hashim

引用次数: 0

The search for blood biomarkers useful in treating atopic dermatitis patients. 对治疗特应性皮炎患者有用的血液生物标志物的研究。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-16 DOI: 10.1080/17512433.2024.2438192

Kenji Izuhara, Satoshi Nunomura, Takeshi Nakahara, Daisuke Onozuka

{"title":"The search for blood biomarkers useful in treating atopic dermatitis patients.","authors":"Kenji Izuhara, Satoshi Nunomura, Takeshi Nakahara, Daisuke Onozuka","doi":"10.1080/17512433.2024.2438192","DOIUrl":"10.1080/17512433.2024.2438192","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is diagnosed based on clinical signs and symptoms as well as on a clinical course lacking distinct laboratory or histological features; however, the recent appearance of molecularly targeted drugs against AD urges us to try to discover and develop biomarkers useful for treating AD patients.Areas covered: This article commenced with a targeted PubMed search using 'atopic dermatitis' and 'biomarker' as keywords. We combined the findings from the B-PAD study that we have recently published and summarized data, particularly those recently published.Expert opinion: Many cells and molecules are listed as potential biomarkers of AD, most of which are type 2 mediators. Among them, CCL17/TARC is now thought to be the most reliable biomarker of AD. During the B-PAD study, we recently found that three biomarkers - squamous cell carcinoma antigen 2 (SCCA2), CCL26/eotaxin-3, and lactose dehydrogenase (LDH) - are better able than CCL17/TARC to assess the clinical severity and disease activity of AD. Moreover, although several biomarkers showed good ability to monitor the efficacy of molecularly targeted drugs against AD. More studies on the discovery and development of biomarkers of AD are awaited to refine treatments for AD patients.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-10"},"PeriodicalIF":3.6,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management. 靶向 HIF-2α：belzutifan 在透明细胞肾癌治疗中的作用。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-13 DOI: 10.1080/17512433.2024.2436433

Alejandro Valdés, Gonzalo Pizarro, Jaime González-Montero, Carlos Rojas, Mauricio Burotto

{"title":"Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management.","authors":"Alejandro Valdés, Gonzalo Pizarro, Jaime González-Montero, Carlos Rojas, Mauricio Burotto","doi":"10.1080/17512433.2024.2436433","DOIUrl":"https://doi.org/10.1080/17512433.2024.2436433","url":null,"abstract":"Introduction: Belzutifan is a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. It targets the von Hippel-Lindau protein (pVHL)-HIF-vascular endothelial growth factor (VEGF) pathway, which is crucial in cellular responses to hypoxia. By inhibiting HIF-2α, belzutifan disrupts the transcription of genes involved in tumor growth and angiogenesis.Areas covered: In this review, we describe the pVHL-HIF-VEGF pathway and how it led to the development of HIF inhibitors, including belzutifan. A search was conducted for trials involving Belzutifan, including phase I-III trials. We describe the relevant toxicity, with emphasis on hypoxia and anemia.Expert opinion: Belzutifan is a relatively safe drug, with manageable adverse events, including anemia and hypoxia as on-target toxicity. Ongoing trials are studying its benefit in overall survival for RCC in first-line treatment and its potential in other malignancies. The LITESPARK-005 trial reported the benefit of belzutifan in progression-free survival (PFS) compared to everolimus in later lines of treatment, with improvement in quality-of-life outcomes. Given its different mechanism of action to currently available treatments, belzutifan is expected to play a prominent role in the treatment of clear cell renal carcinoma and other cancers.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-11"},"PeriodicalIF":3.6,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changing landscapes and increasing relevance of immunotherapy in localized MSI-H gastric adenocarcinoma. 局部MSI-H型胃腺癌免疫治疗前景的变化和相关性的提高。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-10 DOI: 10.1080/17512433.2024.2438178

Jane E Rogers, Jaffer A Ajani

引用次数: 0

The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease. 慢性阻塞性肺疾病患者吸入磷酸二酯酶抑制剂的必要性

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-05 DOI: 10.1080/17512433.2024.2438187

Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera

{"title":"The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease.","authors":"Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera","doi":"10.1080/17512433.2024.2438187","DOIUrl":"10.1080/17512433.2024.2438187","url":null,"abstract":"Introduction: The therapeutic implications of phosphodiesterase (PDE) inhibitors have attracted interest because PDEs are regarded as an intracellular target to be exploited for therapeutic advancements in the treatment of COPD. At present, the only approved approach for the treatment of COPD with PDE inhibitors is the use of an oral PDE4 inhibitor. However, this treatment is not widely employed, primarily due to the narrow therapeutic index associated with oral PDE4 inhibitors, which significantly limits the tolerable dose. The inhalation route represents a viable alternative to the oral route for improving the therapeutic index of PDE4 inhibitors.Areas covered: The development of inhaled PDE4 inhibitors, with a focus on tanimilast and ensifentrine, the latter of which is a dual PDE3/PDE4 inhibitor.Expert opinion: The inhalation route offers several advantages regarding the delivery of PDE inhibitors for the management of COPD. Tanimilast and ensifentrine have been shown to improve lung function, reduce exacerbations and enhance quality of life in COPD patients. However, it has not yet been determined which type of COPD patient might benefit more from inhaled PDE4 inhibitors, and it remains unclear whether concomitant inhibition of PDE3 and PDE4 confers a significant benefit compared to blocking PDE4 alone in COPD.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-13"},"PeriodicalIF":3.6,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview. Avacopan作为anca相关血管炎的附加治疗：药理学综述。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-11-29 DOI: 10.1080/17512433.2024.2432500

Vladimir Tesar, Jan Miroslav Hartinger, Zdenka Hruskova

{"title":"Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview.","authors":"Vladimir Tesar, Jan Miroslav Hartinger, Zdenka Hruskova","doi":"10.1080/17512433.2024.2432500","DOIUrl":"https://doi.org/10.1080/17512433.2024.2432500","url":null,"abstract":"Introduction: ANCA-associated vasculitis (AAV) is a rare, life-threatening disease which may result in serious pulmonary and kidney damage. Cyclophosphamide or rituximab and high-dose glucocorticoids significantly improved patient outcomes, but at the expense of severe complications. Moreover, many patients still relapse and bear a significant burden of both disease- and treatment-related complications. Alternative complement pathway and C5a receptor signaling were demonstrated to play an important role in AAV pathogenesis. Avacopan is selective C5a receptor inhibitor successfully tested in renal AAV as glucocorticoid-sparing agent.Areas covered: Pharmacokinetic/pharmacodynamic properties, clinical efficacy and safety of avacopan, available clinical trials and real-world experience with avacopan.Expert opinion: In the phase 3 trial avacopan was shown to be non-inferior at six and superior at 12 months compared to high-dose glucocorticoids and either cyclophosphamide or rituximab in patients with active AAV. Treatment with avacopan was well tolerated and associated with improved quality of life. In patients with severe renal AAV, renal function improved more in avacopan-treated than in high-dose glucocorticoid-treated patients. Avacopan could thus replace high-dose glucocorticoids to avoid glucocorticoid-related toxicity and to improve long term renal outcome. As avacopan is CYP 3A4 inhibitor and substrate, drug-drug interactions must be considered during the treatment.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-15"},"PeriodicalIF":3.6,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis. 匹伐他汀与阿托伐他汀和罗苏伐他汀相比的新发糖尿病风险：系统回顾和荟萃分析。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-11-25 DOI: 10.1080/17512433.2024.2433603

Harmanjit Singh, Sangambir Kaur, Parul Kaushal, Jatin Sharma, Mandeep Singla

{"title":"Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis.","authors":"Harmanjit Singh, Sangambir Kaur, Parul Kaushal, Jatin Sharma, Mandeep Singla","doi":"10.1080/17512433.2024.2433603","DOIUrl":"https://doi.org/10.1080/17512433.2024.2433603","url":null,"abstract":"Background: Statins are linked to the risk of new-onset diabetes mellitus (NODM). While atorvastatin and rosuvastatin are often associated with NODM, pitavastatin may carry a lower risk. This systematic review and meta-analysis (SRMA) evaluated the impact of pitavastatin on NODM compared to atorvastatin and rosuvastatin.Methods: We conducted a systematic literature search using PubMed, CENTRAL, EMBASE, and ClinicalTrials.gov. Two authors independently screened studies, assessed the risk of bias using Joanna Briggs Institute, Newcastle-Ottawa, and Scottish Intercollegiate Guidelines Network checklists, and extracted data. The analysis was performed using RevMan 5.4.1, and results were represented as risk ratios (RR) with 95% confidence intervals (CI) and heterogeneity was evaluated using the I2 statistic.Results: Of 517 records screened, 13 studies were included, comprising observational studies, and randomized controlled trials. Most of the studies showed pitavastatin to be associated with a lower or no risk of NODM. Meta-analysis revealed that pitavastatin had a lower risk of NODM compared to atorvastatin (RR = 0.86, 95% CI = 0.79-0.93, p = 0.0002) and rosuvastatin (RR = 0.77, 95% CI = 0.71-0.84, p < 0.00001).Conclusion: Pitavastatin poses a lower risk of NODM than other statins, making it a potentially safer option for patients requiring long-term statin therapy.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42022371741.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-9"},"PeriodicalIF":3.6,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A scoping review of the clinical utility of adverse drug reaction causality analysis tools for use in the hospital setting. 药物不良反应因果关系分析工具在医院环境中的临床应用范围综述。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-11-22 DOI: 10.1080/17512433.2024.2429677

Benjamin Deutscher, Keshia De Guzman, Adam La Caze, Nazanin Falconer

{"title":"A scoping review of the clinical utility of adverse drug reaction causality analysis tools for use in the hospital setting.","authors":"Benjamin Deutscher, Keshia De Guzman, Adam La Caze, Nazanin Falconer","doi":"10.1080/17512433.2024.2429677","DOIUrl":"10.1080/17512433.2024.2429677","url":null,"abstract":"Introduction: Identification and monitoring of adverse drug reactions (ADRs) and interventions to reduce ADRs are essential for patient safety in hospitals. Causality analysis (CA) is an approach that helps to determine a causal link between medication and patient harm (i.e. an ADR). While numerous CA tools exist, there is no gold standard.Areas covered: Five online databases were searched to identify studies that evaluated the potential clinical utility of CA tools for ADRs. CA tools were mapped against the Bradford Hill (BH) criteria and included if they adhered to the first seven criteria proposed by BH. Upon the database search, 550 studies were identified, with 41 studies being selected that looked at tools mapped to BH. Thirty-four different CA tools were identified in the included studies.Expert opinion: Naranjo and WHO-UMC were the most reported CA tools for studies examining inter-rater and intra-rater reliability. Naranjo commonly received a 'fair' agreement level while WHO-UMC received a 'substantial' agreement level between raters. Along with kappa statistics, time using the CA tool was also analyzed, with WHO-UMC being the most time-efficient. There does not appear to be one CA tool that can be applied universally to pharmacovigilance efforts in hospital in-patient settings.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-22"},"PeriodicalIF":3.6,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity. 转移性黑色素瘤的免疫检查点抑制：在高毒性下实现高疗效。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-11-21 DOI: 10.1080/17512433.2024.2431513

Joy Justice, Roma A Kankaria, Douglas B Johnson

引用次数: 0